MX2023007192A - Inhibidores de prmt5. - Google Patents
Inhibidores de prmt5.Info
- Publication number
- MX2023007192A MX2023007192A MX2023007192A MX2023007192A MX2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- formula
- prmt5 inhibitors
- prmt5
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126416P | 2020-12-16 | 2020-12-16 | |
| PCT/US2021/063540 WO2022132914A1 (en) | 2020-12-16 | 2021-12-15 | Prmts inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007192A true MX2023007192A (es) | 2023-07-03 |
Family
ID=79927288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007192A MX2023007192A (es) | 2020-12-16 | 2021-12-15 | Inhibidores de prmt5. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11845760B2 (https=) |
| EP (2) | EP4263545B1 (https=) |
| JP (2) | JP7487421B2 (https=) |
| KR (1) | KR20230121820A (https=) |
| AR (1) | AR124369A1 (https=) |
| AU (1) | AU2021400942A1 (https=) |
| CA (1) | CA3204823A1 (https=) |
| CL (1) | CL2023001738A1 (https=) |
| CO (1) | CO2023008167A2 (https=) |
| CR (1) | CR20230310A (https=) |
| IL (1) | IL303451A (https=) |
| JO (1) | JOP20230138A1 (https=) |
| MX (1) | MX2023007192A (https=) |
| PE (1) | PE20231295A1 (https=) |
| TW (1) | TW202233183A (https=) |
| UY (1) | UY39565A (https=) |
| WO (1) | WO2022132914A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2021086879A1 (en) | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| AU2021400942A1 (en) * | 2020-12-16 | 2023-07-06 | Amgen Inc. | PRMT5 inhibitors |
| TW202319046A (zh) * | 2021-08-30 | 2023-05-16 | 美商安進公司 | 用於合成㖠啶衍生物及其中間體之方法 |
| CA3255376A1 (en) * | 2022-04-08 | 2023-10-12 | Amgen Inc. | CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS |
| WO2024002263A1 (zh) * | 2022-06-30 | 2024-01-04 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
| AU2023296592A1 (en) * | 2022-07-01 | 2025-01-30 | Cytosinlab Therapeutics Co., Ltd. | Class of prmt5 inhibitors and use thereof |
| CN119013274A (zh) * | 2022-07-26 | 2024-11-22 | 上海和誉生物医药科技有限公司 | 一种prmt5抑制剂及其制备方法和药学上的应用 |
| AU2023319559B2 (en) * | 2022-08-03 | 2026-04-16 | Abbisko Therapeutics Co., Ltd. | Nitrogen-containing fused three ring prmt5 inhibitor, and preparation method therefor and pharmaceutical use thereof |
| CN119730853A (zh) | 2022-08-15 | 2025-03-28 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的mta协同prmt5抑制剂 |
| JP2025529831A (ja) * | 2022-08-18 | 2025-09-09 | メッドシャイン ディスカバリー インコーポレイテッド | アミド含有複素環誘導体とその使用 |
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
| EP4588920A4 (en) * | 2022-09-26 | 2026-01-28 | Shanghai Apeiron Therapeutics Company Ltd | NEW PRMT5 INHIBITOR AND ITS USE |
| IL319814A (en) * | 2022-09-26 | 2025-05-01 | Shanghai Apeiron Therapeutics Company Ltd | A novel inhibitor of protein arginine methyltransferase 5 and its use |
| CN115677708B (zh) * | 2022-10-19 | 2024-11-29 | 深圳万知达企业管理有限公司 | 一种吡咯并喹喔啉的制备方法 |
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| KR20250119589A (ko) * | 2022-12-05 | 2025-08-07 | 암젠 인크 | 나프티리딘 화합물의 고체 형태 |
| WO2024131901A1 (zh) * | 2022-12-23 | 2024-06-27 | 深圳微芯生物科技股份有限公司 | 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用 |
| CN116332856A (zh) * | 2023-01-04 | 2023-06-27 | 荟达医药科技(上海)有限公司 | 一种4-哒嗪甲醇的合成方法 |
| JP2026504889A (ja) | 2023-01-18 | 2026-02-10 | アンテンジーン・ディスカバリー・リミテッド | Ｐｒｍｔ５阻害化合物およびその使用 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| CN120769934A (zh) * | 2023-02-28 | 2025-10-10 | 美国安进公司 | 用于合成萘啶衍生物及其中间体的方法 |
| CN121241054A (zh) * | 2023-04-14 | 2025-12-30 | 北京双鹤润创科技有限公司 | 氮杂环羰基稠环衍生物及其用途 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| EP4700025A1 (en) | 2023-04-23 | 2026-02-25 | Suzhou Genhouse Bio Co., Ltd. | Amide compound, pharmaceutical composition comprising same, and use thereof |
| CN121358731A (zh) * | 2023-05-17 | 2026-01-16 | 四川科伦博泰生物医药股份有限公司 | 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| US11845749B1 (en) | 2023-07-13 | 2023-12-19 | King Faisal University | Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents |
| WO2025016323A1 (zh) | 2023-07-14 | 2025-01-23 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| CN120943832A (zh) | 2023-08-02 | 2025-11-14 | 成都微芯药业有限公司 | 杂环炔基取代的酰胺衍生物、其制备方法及其应用 |
| AU2024319888A1 (en) | 2023-08-09 | 2026-02-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Heteroaryl compound, preparation method therefor, and use thereof in medicine |
| CN121127472A (zh) | 2023-08-18 | 2025-12-12 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| AU2024356380A1 (en) * | 2023-10-06 | 2026-04-02 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025077856A1 (en) * | 2023-10-12 | 2025-04-17 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Tricyclic-carbonyl-nitrogen heterocyclic derivatives and use thereof |
| US20250154172A1 (en) * | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025166215A1 (en) * | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) * | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) * | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025190395A2 (en) * | 2024-03-14 | 2025-09-18 | Pharmaengine, Inc. | Mta-cooperative prmt5 inhibitor |
| WO2025215153A1 (en) * | 2024-04-10 | 2025-10-16 | Ryvu Therapeutics S.A. | Prmt5 inhibitors |
| WO2025257104A1 (en) | 2024-06-10 | 2025-12-18 | Sandvik Mining And Construction Tools Ab | Diamond and cemented carbide composite material |
| WO2025265110A1 (en) | 2024-06-21 | 2025-12-26 | Amgen Inc. | Oral pharmaceutical compositions comprising a naphthyridine compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106573932B (zh) | 2014-08-22 | 2019-07-30 | 默克专利股份公司 | 吲唑类 |
| PL3665179T3 (pl) | 2017-08-09 | 2021-11-29 | Prelude Therapeutics, Incorporated | Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5) |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| JP7787819B2 (ja) * | 2020-02-12 | 2025-12-17 | アムジェン インコーポレイテッド | 新規ｐｒｍｔ５阻害剤 |
| AU2021400942A1 (en) * | 2020-12-16 | 2023-07-06 | Amgen Inc. | PRMT5 inhibitors |
-
2021
- 2021-12-15 AU AU2021400942A patent/AU2021400942A1/en active Pending
- 2021-12-15 UY UY0001039565A patent/UY39565A/es unknown
- 2021-12-15 WO PCT/US2021/063540 patent/WO2022132914A1/en not_active Ceased
- 2021-12-15 KR KR1020237023776A patent/KR20230121820A/ko active Pending
- 2021-12-15 EP EP21847813.9A patent/EP4263545B1/en active Active
- 2021-12-15 CR CR20230310A patent/CR20230310A/es unknown
- 2021-12-15 CA CA3204823A patent/CA3204823A1/en active Pending
- 2021-12-15 MX MX2023007192A patent/MX2023007192A/es unknown
- 2021-12-15 JP JP2023535834A patent/JP7487421B2/ja active Active
- 2021-12-15 IL IL303451A patent/IL303451A/en unknown
- 2021-12-15 AR ARP210103508A patent/AR124369A1/es unknown
- 2021-12-15 EP EP26161361.6A patent/EP4732837A2/en active Pending
- 2021-12-15 PE PE2023001893A patent/PE20231295A1/es unknown
- 2021-12-15 TW TW110146964A patent/TW202233183A/zh unknown
- 2021-12-15 US US17/552,016 patent/US11845760B2/en active Active
-
2023
- 2023-06-14 JO JOJO/P/2023/0138A patent/JOP20230138A1/ar unknown
- 2023-06-14 CL CL2023001738A patent/CL2023001738A1/es unknown
- 2023-06-22 CO CONC2023/0008167A patent/CO2023008167A2/es unknown
- 2023-11-06 US US18/502,780 patent/US20240092794A1/en active Pending
-
2024
- 2024-05-07 JP JP2024075101A patent/JP2024102236A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4263545A1 (en) | 2023-10-25 |
| US20220194955A1 (en) | 2022-06-23 |
| AU2021400942A9 (en) | 2024-10-24 |
| US11845760B2 (en) | 2023-12-19 |
| TW202233183A (zh) | 2022-09-01 |
| CO2023008167A2 (es) | 2023-07-21 |
| IL303451A (en) | 2023-08-01 |
| UY39565A (es) | 2022-06-30 |
| KR20230121820A (ko) | 2023-08-21 |
| JP2023550530A (ja) | 2023-12-01 |
| CN116888120A (zh) | 2023-10-13 |
| EP4732837A2 (en) | 2026-04-29 |
| AR124369A1 (es) | 2023-03-22 |
| CL2023001738A1 (es) | 2023-11-17 |
| US20240092794A1 (en) | 2024-03-21 |
| PE20231295A1 (es) | 2023-08-22 |
| AU2021400942A1 (en) | 2023-07-06 |
| JP2024102236A (ja) | 2024-07-30 |
| CR20230310A (es) | 2023-09-01 |
| JP7487421B2 (ja) | 2024-05-20 |
| JOP20230138A1 (ar) | 2023-06-14 |
| CA3204823A1 (en) | 2022-06-23 |
| WO2022132914A1 (en) | 2022-06-23 |
| EP4263545B1 (en) | 2026-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007192A (es) | Inhibidores de prmt5. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| SA523440916B1 (ar) | Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2024011056A (es) | Compuesto heterociclico para inducir la degradacion de la proteina kras mutante g12d. | |
| CU20210065A7 (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2 | |
| JOP20220282A1 (ar) | مركبات مفيدة لتثبيط كيناز ret | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CY1125784T1 (el) | Υποκατεστημενες δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της prmt5 | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| EA200870373A1 (ru) | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
| JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| JOP20230275A1 (ar) | معدلات trex1 | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين | |
| BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto | |
| GEAP202516217A (en) | Compounds and compositions as sppl2a inhibitors | |
| EA202190452A1 (ru) | Ингибиторы cdk8/19 | |
| JOP20250005A1 (ar) | مثبطات التيروسين كيناز 2 واستخداماتها | |
| MX2023015246A (es) | Compuestos pirimidinicos para usar como inhibidores de map4k1. |